Figure 2
ONO-1301 ameliorates hypoxia in the spinal cord of mSOD1G93A mice. (a) Western blot analysis revealed significantly decreased HIF-1α expression in the spinal cords of 120-day-old ONO-1301-MS–treated mSOD1G93A mice relative to vehicle-treated mSOD1G93A mice. (b) Fixed frozen sections of lumbar cord of mSOD1G93A mice were stained with anti-HIF-1α antibodies. Representative images show reduced immunoreactivity of HIF-1α in 120-day-old ONO-1301-MS–treated mSOD1G93A mice compared to age-matched vehicle-treated control mice (n = 3 mice per group). Scale bar = 50 μm. (c,d) Quantitative RT-PCR analyses for erythropoietin (EPO), vascular endothelial growth factor (VEGF) (c) and osteopontin (OPN) (d) in spinal cords of ONO-1301-MS–treated mSOD1G93A mice and vehicle-treated control mice at 120 days of age (n = 5 per group). The expression levels of EPO (P = 0.014) and VEGF (P = 0.036) were significantly reduced in the ONO-1301-MS–treated group. Data are expressed as the mean ± SEM. *P < 0.05, **P < 0.01.
